PaxMedica (PaxMedica) Interest Expense : $-0.01 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is PaxMedica Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PaxMedica's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PaxMedica's Operating Income for the three months ended in Mar. 2024 was $ -3.69 Mil. PaxMedica's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. PaxMedica has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

PaxMedica Interest Expense Historical Data

The historical data trend for PaxMedica's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PaxMedica Interest Expense Chart

PaxMedica Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.61

-2.81

-0.01

PaxMedica Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

PaxMedica Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

PaxMedica (OTCPK:PXMD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PaxMedica's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-3.69 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.00 Mil.

PaxMedica's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

PaxMedica had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

PaxMedica (PaxMedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591

Website

https://www.paxmedica.com

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

Executives

Zachary Rome	director, officer: Chief Operating Officer	C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Derby	director, officer: Executive Chairman	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Howard J. Weisman	director, officer: Chief Executive Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle	director	900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho	director	22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough	officer: Chief Medical Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc	10 percent owner	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon	officer: Chief Financial Officer	2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748